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Abstract
Background: The purpose of this analysis was to compare health care costs and utilization among COPD patients
who had long-acting beta-2 agonist (LABA) OR long-acting muscarinic antagonist (LAMA); LABA AND LAMA; or
LABA, LAMA, AND inhaled corticosteroid (ICS) prescription claims.
Methods: This was a 12 month pre-post, retrospective analysis using COPD patients in a national administrative
insurance database. Propensity score and exact matching were used to match patients 1:1:1 between the LABA or
LAMA (formoterol, salmeterol, or tiotropium), LABA and LAMA (tiotropium/formoterol or tiotropium/salmeterol),
and LABA, LAMA and ICS (bronchodilators plus steroid) groups. Post-period comparisons were evaluated with
analysis of covariance. Costs were evaluated from a commercial payer perspective.
Results: A total of 523 patients were matched using 29 pre-period variables (e.g., demographics, medication exposure).
Post-match assessments indicated balance among the cohorts. COPD-related costs differed among groups (LABA or
LAMA $2,051 SE = 91; LABA and LAMA $2,823 SE = 62; LABA, LAMA and ICS $3,546 SE = 89; all p < .0001) with the
differences driven by study medication costs. However, non-study COPD medication costs were higher for the LABA or
LAMA therapy group ($911 SE = 91) compared to the LABA and LAMA therapy group ($668 SE = 58; p = 0.0238) and
non-study respiratory medications were approximately $100 greater for the LABA or LAMA therapy group relative to
both LABA and LAMA (p = .0018) and LABA, LAMA, and ICS (p = .0071) therapy groups. While there was no observed
difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA
(25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of
patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001)
and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).
Conclusions: Significant cost differences driven mainly by pharmaceuticals were observed among LABA or LAMA,
LABA and LAMA and LABA, LAMA and ICS therapies. A COPD-related cost offset was observed from single
bronchodilator to two bronchodilators. Addition of an ICS with two bronchodilators resulted in higher treatment
costs without reduction in other COPD-related costs compared with two bronchodilators.
Background
Chronic obstructive pulmonary disease (COPD) is a
lung condition characterized by persistent obstruction of
bronchial airflow that is not fully reversible. While the
disease is progressive, it is possible that treatment may
slow the worsening of symptoms.
Treatment includes both pharmacologic and non-
pharmacologic alternatives. The Global Initiative for
Chronic Obstructive Lung Disease (GOLD) treatment
guidelines recommend short acting bronchodilators for
mild COPD, adding one or more bronchodilators for
moderate to severe COPD, and only adding inhaled
steroids for patients with repeated exacerbations [1].
Combining bronchodilators with different mechanisms
of action may increase the degree of bronchodilation
with equivalent or lesser side effects [2] yet this seems
to be a much underutilized form of therapy. The
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from published randomized controlled clinical trials
in patients with moderate-to-severe COPD is limited
compared to its application in clinical practice [3].
Regular treatment with inhaled glucocorticoids has
been shown to reduce the frequency of exacerbations
in patients with severe or very severe COPD [4] with
repeated exacerbation [5] however the likelihood of
pneumonia increases and mortality is not decreased
[6]. Studies have suggested that patients on LABA
and LAMA bronchodilator therapy (once daily
LAMA plus twice daily LABA) have poor persistence
rates, yet instead of dealing with the adherence
issues they are often switched to a combination pro-
duct combining a single bronchodilator and inhaled
steroid [7].
COPD treatment goals are to relieve symptoms, pre-
vent disease progression, improve exercise tolerance,
improve health status, prevent and treat complications
and exacerbations and reduce mortality [1]. There are
multiple clinical, humanistic and economic outcomes
that are important for the comprehensive evaluation of
COPD [8]. These outcomes include variables such as
activity level, symptoms, pulmonary function, exercise
tolerance, use of rescue medications, satisfaction, quality
of life, mortality, and resource use. This study focused
on the effect of GOLD guideline recommended pharma-
cologic treatment on resource utilization and costs,
which are outcomes that have a direct impact from a
payer perspective.
Methods
Study Design
This study was a retrospective, propensity matched-
cohort treatment group comparison. An index date was
assigned as the date of the first claim for tiotropium,
formoterol or salmeterol between January 1, 2006 and
June 30, 2007. 12 month pre-index date and 12 month
post-index date observation period was used for the eva-
luation. Randomized trials assume comparison groups
are balanced based on random assignment and large
sample sizes, whereas retrospective studies frequently
use statistical or logical controls to create balanced com-
parison groups. In this study, a multinomial propensity
score matched group approach was employed using
patient demographics and other variables from the 12-
month pre-index date period. Patients were only
included in the analysis if suitable matches were found
across the three treatment groups.
Treatment Group Assignment
The project focused on the long acting inhaled medica-
tions listed in Table 1. These products were of interest
because they have been shown to relieve symptoms,
increase exercise capacity, improve quality of life and
reduce exacerbations to a greater extent than short-act-
ing bronchodilators, and today, they are the foundation
treatment for this disease [9]. Other therapy combina-
tions with methylxanthines, short acting beta2-agonists,
short acting anticholinergics, oral or other inhaled glu-
cocorticoids could have been studied, but they were not
included in this analysis to minimize the duration of
action and delivery route differences in the treatment
alternatives.
The following rules were applied to assign patients to
treatment groups:Group 1: LABA or LAMA
a) Patients must have had only claims for one of the
study drugs (tiotropium, formoterol or salmeterol)
during the 12 month post index period.
b) Patients must have had at least 30 days of medi-
cation available in each quarter of the post index
year following index to be considered “on therapy”.
c) Could not have 30 days or more overlap with any
study drugs.
d) Patients using inhaled steroids (budesonide, fluti-
casone) were excludedGroup 2: LABA and LAMA
a) To qualify for the LABA and LAMA study group,
patients must have had prescriptions for either tio-
tropium in combination with formoterol or tiotro-
pium in combination with salmeterol during the
post-index year.
b) Patients must have had at least 30 days of over-
lapping therapy on two of the drugs during each
quarter of the post index year to be considered “on
therapy”.
c) Patients must not have had any prescriptions for
any drug that might make them eligible for the
LABA, LAMA, and ICS group during the post-index
year.
d) Patients using inhaled steroids (budesonide, fluti-
casone) were excludedGroup 3: LABA, LAMA, and
ICS
a) To be assigned to the LABA, LAMA, and ICS
group patients must have had prescriptions for
either tiotropium in combination with fluticasone/
salmeterol or tiotropium in combination with bude-
sonide/formoterol during the post index year.
b) Patients must have had at least 30 days of over-
lapping therapy on three of the drugs during each
quarter of the post index year to be considered “on
therapy”.
Once a treatment group was assigned, a patient’sf i r s t
prescription for tiotropium, formoterol or salmeterol
was used to establish their index date.
Kozma et al. BMC Pulmonary Medicine 2011, 11:61
http://www.biomedcentral.com/1471-2466/11/61
Page 2 of 9Study Periods
Figure 1 presents a diagram of the study period, illustrat-
ing the latest possible index date of June 30
th, and an ear-
lier potential date of February 11 as examples, showing
the requirement for 12 months of data from the pre- and
post-index date periods. The utilization data covers the
time period from January 1, 2005 through June 30, 2008.
A period of one year prior to the index prescription date
("pre-period”) was used to apply the inclusion and exclu-
sion criteria and to match patients to form three matched
cohorts. Since the available data began on January 1,
2005, the earliest possible date for patient identification
was January 1, 2006. This identification period continued
until June 30, 2007, which allowed one full year of follow
up observation ("post-period”).
Inclusion/Exclusion Criteria
The following inclusion and exclusion criteria were
employed to ensure that study patients were accurately
identified as COPD patients, were not compromised by
other respiratory conditions, and had complete claims
information during the study period.
Inclusion Criteria
The following criteria, all of which must have been satis-
fied, were used to identify patients for this study:
￿ Have at least one diagnosis for COPD (490.xx-492.
xx,494.xx,496.xx) in any diagnosis field anytime in the
available data.
￿ Have a prescription claim for one of the study medi-
cations between Jan 1, 2006 - June 30, 2007. The date of
the first study medication is the index date.
￿ Have at least 30 days of medication per quarter in
the 12 months post-index meeting the criteria described
under study group assignment.
￿ Have continuous enrollment for 12 months pre and
12 months post index date. Be at least 40 years of age
on index date.
Exclusion Criteria
If any one of the following criteria was met, the patient
was excluded from the study.
￿ Incomplete or invalid data on variables that were
used in the either the propensity-match analysis (e.g.
age, gender) or post-index analysis (e.g. costs).
Table 1 Generic names of the long-acting inhaled drug
products that were used to assign patients to groups.
Treatment
Group
Generic name
LABA OR LAMA* Formoterol Fumarate
Salmeterol Xinafoate
Tiotropium Bromide
LABA AND
LAMA*
Tiotropium Bromide/Formoterol Fumarate
Tiotropium Bromide/Salmeterol Xinafoate
LABA, LAMA
AND ICS
Tiotropium Bromide/Fluticasone Propionate/
Salmeterol Xinafoate
Tiotropium Bromide/Budesonide/Formoterol
Fumarate
* Consistent with GOLD guidelines, refers to bronchodilator therapy.
Beginning of study period: 
January 1, 2005
End of study period: 
June 30, 2008
Patient Identification Period
January 1, 2006 June 30, 2007
Example– Patient 1
Index
February 11, 2006
Observation period
12 months 12 months
Study Period
Example– Patient 2
Index
June 30, 2007
Observation period
12 months 12 months
Study Period:  January 1, 2005  – June 30, 2008                              Patient Identification Period:  January 1, 2006  – June 30, 2007
Pre-period Post period
Post period Pre-period
Figure 1 Graphic representation of the study period and the earliest and latest possible patient observation periods.
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tic fibrosis (277.0x), or respiratory tract cancer (160.x-
164.x) at any time in the available data.
￿ Missing or zero quantity or days supply for any
study drug claims in the Study Period.
Propensity Match Procedure
After patients were assigned to the three treatment
groups, and after the application of the inclusion and
exclusion criteria, a 1:1:1 propensity match was con-
ducted to provide evidence of equivalence between the
comparison groups. A multinomial logit propensity
model was employed with a methodology published by
Rosenbaum and Rubin [10] and extended to more than
two groups by Imbens [11]. Our approach used exact
matching and nearest available Mahalanobis distance
matching within calipers defined by the propensity
scores. The process created three treatment groups that
were closely matched on the pre-index date characteris-
tics (see results tables for a listing of the variables
included in the analysis). Exact matching was performed
on 4 of these variables (gender, south region, pneumonia
and ischemic heart disease). Mahalanobis distance
matching within calipers for the propensity score was
used to select the best matching patients using the
remaining variables. To account for correlation that may
have been introduced by matching patients, paired tests
were used to test for any differences remaining within
the matched variables. Independent tests were also eval-
uated since they provide additional information on the
mean effects. Since the results were similar and the
paired tests are more conservative, only the results of
the paired tests are presented.
Dichotomous indicators were included in the propen-
sity model for most frequently reported physician types
(e.g., cardiovascular specialist and internists) and for
specific comorbidities based on presence of diagnosis
codes (e.g., neoplasms, pneumonia, hypertension, heart
failure, respiratory illness, diabetes, ischemic heart dis-
ease, pulmonary vascular disease and stroke). Use of the
Charlson comorbidity index was evaluated, however,
better model fit was observed with the specific comor-
bidity indicators and the prescription measure (i.e., the
Rx comorbidity score). The prescription measure is a
continuous variable that is the count of number of dif-
ferent medication classes (i.e., treated comorbidities)
from which patients had prescriptions dispensed. The
propensity model also includes the percentage of days in
the pre-period for which patient had COPD medications
available. This was assumed to be a measure of pre-per-
iod medication adherence with COPD medications. Uti-
lization and cost variables were included in the
propensity model (e.g., presence of a hospitalization or
ER visit in the pre-period, COPD-related total cost in
the pre-period, number of hospital visits, number of
hospitalized days, number of ER visits, and number of
outpatient visits). Finally, an indicator for payer status
was included in the model (i.e., Medicare and other plan
type). See results tables for a listing of the variables
included in the analysis
Outcome Comparisons
A generalized estimating equations (GEE) model with
repeated measures was used to conduct analyses of cov-
ariance tests for differences in primary outcomes among
the three propensity matched groups. This method was
selected to enable adjustment of potentially higher cor-
relation between matched patients compared to non-
matched patients. The model utilized the normal distri-
bution and an exchangeable covariance matrix. Use of
the gamma distribution was evaluated; however, the
normal distribution provided better model fit. A variable
for days of study medication exposure during the year
prior to Index date was included as a covariate in all
outcome models. Differences in least-square mean costs
and utilization among treatment groups were then
tested.
The primary study outcomes, health care costs and
utilization rates, were compared for the three propensity
matched cohorts during the 12 month post-index date
period. Total costs were evaluated as well as costs by
type of service and COPD relatedness (i.e., COPD-
related or non-COPD related). Cost was evaluated from
a commercial insurer perspective and included amounts
that would typically be reimbursed by a commercial
payer. Types of service included inpatient services,
emergency room services, outpatient services, and phar-
macy. Utilization rates (e.g. visits/year) were also sum-
marized overall and by service category.
Post-index date comparisons among the matched
groups were conducted using a) GEE models adjusting
for repeated measures with follow-up pairwise tests for
each continuous variable or b) Cochran’sQt e s t sw i t h
follow-up pairwise McNemar’s tests for categorical vari-
ables. “Days of study medication exposure” during the
pre-index date year was used as a covariate in the post-
period comparisons. To make the costs incurred across
the study period comparable, the consumer price index
(CPI) was used to bring all costs to June, 2008 using the
US city average medical care services CPI (not season-
ally adjusted) to escalate earlier costs to June, 2008 [12].
The data source for this study was the MarketScan data-
base, a national managed care claims dataset. The data
w a ss e l e c t e df r o mt h eM a r k e t S c a nd a t a b a s ef r o mJ a n u -
ary 1, 2005 through June 30, 2008. SAS Version 9.1 was
used for all analyses. No adjustments were made for
multiple comparisons as part of the propensity analyses.
The Marketscan data are irreversibly de-identified and
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Accountability Act of 1996, no institutional review
board approval or waiver of authorization was required.
Results
Of the 49 million unique patients in the database during
the study period, 163,174 used at least 1 of the COPD
study drugs, and 15,857 met the remaining inclusion
and exclusion criteria which qualified them to be
assigned to one of the three treatment groups as shown
in Table 2. The majority of patients were excluded
based on diagnoses, eligibility and minimum drug expo-
sure requirements. The starting size of the sample that
had diagnosed COPD without asthma, which were con-
tinuously eligible for services over the study period and
had minimum exposure to study medications, was
26,245. Of these, 16,556 had one of the drug patterns of
interest and after exclusions for missing enrollment
information and negative dollar amounts the final sam-
ple size was 15,857. A total of 592 were assigned to the
LABA and LAMA group providing evidence that this
therapy is underutilized based on the recommendations
in the GOLD guidelines.
Propensity Match
Of the 592 patients in the LABA and LAMA group, a
1:1:1 match was made for 523 of the patients. The
remaining patients did not have a suitable match in the
other groups for inclusion into the 3 matched cohorts.
Tables 3 and 4 show the comparability of the three
matched cohorts on the 29 pre-index date match vari-
ables. In addition, plots of the propensity score logits
were visually inspected and showed extensive overlap
with similar distributions across cohorts (data not
shown).
Outcome Comparisons
When the three matched cohorts were compared on the
outcome of total commercial paid amounts, the LABA,
LAMA, and ICS cohort with a cost of $9,142/year on
average, had significantly higher costs versus the LABA
o rL A M Ag r o u pa t$ 7 , 6 6 4o na v e r a g e( p=0 . 0 1 9 7 ) .
When total prescription costs were compared statisti-
cally, all 3 groups differed from one another signifi-
cantly. The incrementally higher expenditures for each
successive level of therapy did not result in an overall
health care cost savings or offset when costs were
viewed in the aggregate as shown in Figure 2.
The same pattern was observed when COPD-related
costs were compared, which also differed among groups
( L A B Ao rL A M A$ 2 , 0 5 1S E9 1 ;L A B Aa n dL A M A
$2,823 SE 62; LABA, LAMA and ICS $3,546 SE 89; all p
< .0001) with the differences driven primarily by study
medication costs.
Partial offset of the COPD-related cost was observed
when expenditures were classified by service type and
Table 2 Attrition of patients using the inclusion/exclusion criteria and assignment to three treatment groups before
1:1:1 matching process.
Criteria Removed Remaining
Number of patients MarketScan database (1/2005-6/2008) NA 49,042,666
Have at least one COPD Study Drug between Jan 1, 2006 - Jun 30, 2007) 48,879,492 163,174
Omit patients with missing or zero quantity or days supply values on any COPD study prescription claim 2,785 160,389
Require at least one diagnosis for COPD (490.xx-492.xx, 494.xx, 496.xx) in any diagnosis field at any time in the data. 44,560 115,829
Omit patients with RX = 0 on any claims medical during the study period; this is MarketScan’s indicator that the pharmacy
claims were incomplete or unavailable.
690 115,139
Omit patients with a diagnosis of asthma (ICD-9-CM 493.xx), cystic fibrosis (277.0x), or respiratory tract cancer (160.x-164.x)
at any time during the available data.
51,149 63,990
Require 12 months pre/12 months post index continuous eligibility 19,871 44,119
Include only patients aged 40 or older on index date 205 43,914
Have at least 30 days per quarter coverage for index prescription 17,669 26,245
Have at least one prescription for tiotropium, formoterol or salmeterol with treatment patterns that were in keeping with
one of the three treatment groups (LABA or LAMA, LABA and LAMA or LABA, LAMA and ICS therapy)
9,689 16,556
Omit patients with missing PLANTYPs in CCAE enrollment data 55 16,501
Omit patients with negative dollar amounts in the NETPAY field. 644 15,857
TOTAL 15,857
Treatment group distribution prior to propensity match: n %
LABA or LAMA group 8,334 52.6
LABA and LAMA group 592 3.7
LABA, LAMA, and ICS group 6,931 43.7
Kozma et al. BMC Pulmonary Medicine 2011, 11:61
http://www.biomedcentral.com/1471-2466/11/61
Page 5 of 9their relationship to COPD vs. non-COPD expenditure
a ss h o w ni nF i g u r e3w i t hs t u d yd r u gc o s t sn o ts h o w n .
The matched cohort treated with LABA or LAMA had
significantly higher COPD-related expenditures (after
study drug was excluded) compared to the matched
cohort treated with LABA and LAMA therapy. The
expenditure for other respiratory prescriptions (albu-
terol, theophylline, etc.) was also higher in the LABA or
LAMA cohort compared to the LABA and LAMA or
LABA, LAMA and ICS therapy cohorts (p = 0.0018 and
Table 3 Comparison of three matched cohorts on their pre-index date categorical variables using McNemar’s test for
paired observations.
LABA or LAMATx
(n = 523)
LABA and LAMA Tx
(n = 523)
LABA, LAMA, and ICS Tx
(n = 523)
Significant Pairwise tests*
Categorical Variables n (%) n (%) n (%)
Male 280 (53.5) 280 (53.5) 280 (53.5) NONE
North 210 (40.2) 218 (41.7) 222 (42.4) NONE
Northeast 52 (9.9) 50 (9.6) 49 (9.4) NONE
South 189 (36.1) 189 (36.1) 189 (36.1) NONE
West 71 (13.6) 65 (12.4) 61 (11.7) NONE
Cardiovascular specialist 170 (32.5) 181 (34.6) 176 (33.7) NONE
Internist 253 (48.4) 260 (49.7) 264 (50.5) NONE
Neoplasms 128 (24.5) 146 (27.9) 149 (28.5) NONE
Pneumonia 51 (9.8) 51 (9.8) 51 (9.8) NONE
Hypertension 187 (35.8) 209 (40.0) 203 (38.8) NONE
Heart failure 59 (11.3) 53 (10.1) 56 (10.7) NONE
Diseases of the respiratory system 482 (92.2) 475 (90.8) 477 (91.2) NONE
Diabetes 67 (12.8) 71 (13.6) 73 (14.0) NONE
Ischemic heart disease 116 (22.2) 116 (22.2) 116 (22.2) NONE
Pulmonary vascular disease 16 (3.1) 19 (3.6) 15 (2.9) NONE
Stroke 40 (7.6) 45 (8.6) 37 (7.1) NONE
Hospital visit (≥ 1) 89 (17.0) 81 (15.5) 68 (13.0) NONE
ER visit (≥ 1) 148 (28.3) 142 (27.2) 129 (24.7) NONE
ER visit leading to hospitalization (≥ 1) 62 (11.9) 53 (10.1) 55 (10.5) NONE
Non-Medicare payer type** 156 (29.8) 146 (27.9) 161 (30.8) NONE
*Based on McNemar’s tests for paired observations. Pairwise tests were conducted and results are listed using the following notation: M = LABA or LAMA, D =
LABA and LAMA, T = LABA, LAMA, ICS, NONE = No sig dif. All variables were derived from the 12 month pre-index period.
**An indicator variable for Medicare versus Non-Medicare plan type was used. The plan type of Non-Medicare included Comprehensive, HMO, POS, EPO, PPO,
and CDHP.
Table 4 Comparison of three matched cohorts on their pre-index date continuous match variables using paired t-tests.
Pre-Index Continuous Variables LABA or LAMATx LABA and LAMA Tx LABA, LAMA, and ICS Tx Significant Pairwise Paired t-tests*
(n = 523) (n = 523) (n = 523)
LS Mean (SE) LS Mean (SE) LS Mean (SE)
Age 70.0 (9.4) 70.7 (9.4) 70.4 (9.3) NONE
Rx comorbidity score 6.2 (2.6) 6.4 (2.8) 6.2 (2.6) NONE
% Days COPD medication exposure 64.3 (32.3) 66.3 (33.8) 63.2 (32.8) DvT
Average copay amount 12.9 (12.4) 13.9 (13.4) 14.0 (12.4) NONE
Total COPD-related costs 1,895.9 (1914.5) 1,987.7 (2411.5) 1,973.1 (2216.6) NONE
Number of hospital visits 0.2 (0.5) 0.2 (0.5) 0.2 (0.5) NONE
Number of days in hospital 0.8 (2.5) 0.8 (2.3) 0.6 (2.3) NONE
Number of emergency room visits 0.5 (1.1) 0.4 (1.0) 0.4 (0.8) NONE
Number of outpatient visits 21.7 (16.8) 22.4 (16.7) 20.9 (18.8) NONE
*Pairwise paired t-tests for dependent measures were conducted and pairs resulting in a significant p-value are listed (M = LABA or LAMA, D = LABA and LAMA,
T = LABA, LAMA, ICS, NONE = No sig dif). All variables were derived from the 12 month pre-period.
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trended to have higher expenditures for inpatient and
outpatient services, however these differences were not
statistically significant when then these service types
were analyzed separately.
Paradoxically, while expenditure trended higher in the
mono therapy group for outpatient service, the percent
of patients using outpatient services (73.8%) was lower
than in the LABA and LAMA therapy cohort (89.7%, p
< 0.0001) and the LABA, LAMA and ICS therapy cohort
(85.3%, p < 0.0001). In addition, the number of outpati-
ent visits per patient per year was also lower in the
LABA or LAMA cohort (22.3 visits/year) compared to
the LABA and LAMA therapy cohort (25.5 visits/year, p
< 0.0001); but not significantly different than the LABA,
LAMA and ICS therapy cohort (23.5 visits/year, p =
0.2700). When only COPD-related visits are compared,
the LABA and LAMA therapy cohort used 8.5 COPD-
related visits/year, compared to the LABA, LAMA and
ICS therapy cohort using 7.3 COPD-related visits/year
(p = 0.0355).
Discussion
This study using existing retrospective data employing a
statistical method to identify matched cohorts of
patients compared the matched cohorts on the pre-spe-
cified economic outcomes. Such methods are not likely
to replace the randomized clinical trial, yet they have
other advantages in that large samples of patients can
be studied in real-world settings using existing data.
Even before any comparisons were made between
cohorts, an important finding was that only 3.7% of all
the COPD patients assigned to a treatment group were
using combination long-acting inhaled beta agonist and
antimuscarinic bronchodilator therapy, in spite of the
fact that this regimen is recommended by GOLD before
adding ICS therapy. This low percentage may indicate
that COPD patients do not stay on LABA and LAMA
therapy for long before they are elevated to LABA,
LAMA and ICS therapy, or that patients may progress
directly from LABA or LAMA to LABA, LAMA and
ICS therapy.
Although the LABA and LAMA therapy group was
small compared to the size of the other 2 groups, the
matching process successfully resulted in three very
similar cohorts using the pre-index date characteristics
available in the data. If FEV-1 or other clinical end-
points were available, the match between cohorts might
have been further enhanced, however those data ele-
ments are not available in the administrative claims
dataset used in this study.
As the number of COPD treatments increased from
t h es i n g l et ot h eL A B A ,L A M Aa n dI C St h e r a p y
cohorts, the cost of prescription treatment increased;
and there was a partial offset in COPD related costs
between the LABA or LAMA group and the LABA and
947 795 891
2,286 2,067 1,966
4,367 5,516 6,227
0
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Therapy
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<.0001 0.029 <.0001 Prescriptions
0.3928 0.6867 0.5423 Outpatient 
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0.8541 0.7371 0.5596 Inpatient 
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0.7389 0.5289 0.3276 Emergency 
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LABA or 
LAMA
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LAMA, & 
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LABA & 
LAMA
vs. 
LABA, 
LAMA, & 
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vs.  
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9,142
Figure 2 Average overall health care costs per patient in each matched treatment cohort. (n = 523 patients per matched cohort)
(Emergency Room costs are not visible due to the very small magnitude).
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costs were on average $1149 higher in the LABA and
LAMA therapy group compared to the single therapy
group, and the COPD-related costs were $243 lower,
excluding the cost of the study drugs. A similar offset
from other COPD-related costs was not seen when the
LABA and LAMA therapy group was compared to the
LABA, LAMA and ICS therapy group. While other clin-
ical or quality-of life outcomes might have been
improved in the LABA, LAMA and ICS therapy cohort,
the economic outcomes as measured by the administra-
tive claims data did not improve in the LABA, LAMA
and ICS therapy cohort.
The LABA or LAMA cohort had higher COPD related
cost, however the number of outpatient visits and the
percent of patients with visits were significantly lower.
One potential explanation of this observation was that
the visits within the LABA or LAMA cohort were more
expensive per visit, possibly indicating they were for
treatment of exacerbations, and not for routine visits.
Because many patients were excluded in the match
selection process, these findings should not be taken to
represent what would be seen in all COPD patients. The
findings pertain to the matched cohorts which include
the LABA and LAMA therapy cohort. This indicates the
need for additional research regarding the potential ben-
efits of maximizing LABA and LAMA therapy before
moving a COPD patient to LABA, LAMA and ICS ther-
apy with inhaled glucocorticoids. A 1:1:1 propensity
match was used in this analysis. It is possible that alter-
native selection or matching strategies could lead to dif-
ferent results. Further exploration using alternative
techniques is warranted.
While the goal of the study was to evaluate patients
who are on a stable therapy, assignment of patients to
static groups may make detection of differences in utili-
zation less likely. Little is known about the process that
physicians use when deciding to make changes in
patient medications; however it might be reasonable to
expect that changes are more likely to occur when
patients are having problems and that stable patients
have lower levels of utilization. Follow-up studies may
f o c u so nt h et r a n s i t i o n so rs w i t c h e si nt h e r a p ya m o n g
the LABA or LAMA, LABA and LAMA, or LABA,
LAMA and ICS therapy options.
The use of claims based data for conducting propen-
sity matching is limited to the variables that are
included in an administrative database. No objective
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small magnitude).
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were available. While the 29 variables used in the match
process indicated the 3 cohorts were very well matched,
the potential exists that some other characteristic not
captured by the 29 matched variables may explain a dif-
ference between the 3 cohorts at baseline.
As the health care system works to achieve meaningful
use of electronic medical records, studies such as this
may become more common and more advanced as we
gain insights to improve health care quality and/or
lower cost by analyzing real-world data. Incorporating
clinical outcomes and functional status into an analysis
such as this could provide additional benefits.
Conclusions
The findings from this analysis of administrative data
are consistent with the randomized trial findings and
recommendations within the GOLD COPD treatment
guidelines. The use of LABA or LAMA alone may result
in higher COPD-related management costs compared to
managing stable patients with a LABA and LAMA regi-
men or a LABA, LAMA and ICS regimen. This study
also indicates that a stable COPD population managed
with LABA, LAMA and ICS regimen including inhaled
corticosteroids may have higher treatment costs without
an offset in their other COPD-related costs compared to
a matched cohort managed with a LABA and LAMA
regimen. Because no information on clinical or quality
of life outcomes were assessed, it is not possible to
report the effect of additional levels of COPD therapy
on these non-economic outcomes.
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